Key Takeaways
- ARK Invest offloaded 182,767 shares of Strata Critical Medical through two ETFs on April 13, 2026, valued at approximately $738,378
- This sale continues a week-long trend, with ARK previously unloading more than 75,000 shares on April 10
- Strata Critical Medical operates as a healthcare logistics provider specializing in organ transplant transportation across the United States
- Two prominent Wall Street analysts launched coverage with Buy recommendations and $8 price targets
- Analysts’ consensus price target of $9.08 suggests potential gains exceeding 120% from the stock’s current $4.12 level
Cathie Wood’s investment firm ARK Invest has maintained a consistent selling pattern in Strata Critical Medical throughout the past week. During the April 13, 2026 trading session, ARK offloaded 182,767 shares via the ARK Autonomous Technology & Robotics ETF and the ARK Space Exploration & Innovation ETF. The transaction totaled roughly $738,378 in value.
Strata Critical Medical, Inc., SRTA
The selling activity represents an ongoing strategy rather than an isolated event. ARK previously disposed of over 75,000 shares on April 10, with additional sales recorded throughout the same timeframe. This consistent activity suggests a calculated approach to downsizing the firm’s stake in the company.
Strata Critical Medical operates as a small-capitalization healthcare logistics enterprise. The company manages among the most extensive air transportation and surgical service networks dedicated to organ transplant facilities throughout the United States. Strata positions itself as the sole comprehensive platform serving organ transplant logistics needs.
Shares currently trade near $4.12 each. The stock finished 2% up on April 13 and has climbed 51% during the past twelve months, placing it within penny stock classification.
Wall Street Maintains Optimistic Outlook Amid ARK’s Exit
While ARK continues reducing its position, two major Wall Street analysts recently launched coverage with favorable assessments.
B. Riley analyst Yuan Zhi began tracking the stock with a Buy recommendation and established an $8 price objective. Zhi highlighted the company’s dominant position within the U.S. organ transplant sector and emphasized its status as the sole provider delivering comprehensive logistics services in this niche.
Craig-Hallum analyst Bill Bonello similarly initiated coverage with a Buy rating alongside an $8 target price. Bonello noted the company has undergone significant transformations during the previous year, though these improvements remain undervalued in the current market price.
Both analysts anticipate growing investor confidence as the company delivers clearer financial performance.
Analyst Consensus and Price Projections
According to TipRanks data, Strata Critical Medical carries a Strong Buy consensus rating supported by three unanimous Buy recommendations.
The consensus analyst price target stands at $9.08. This projection indicates potential appreciation exceeding 120% from the present price level of approximately $4.12.
Bonello further suggested that prevailing analyst forecasts for the company may prove understated, indicating the possibility of returns surpassing current projections.
ARK has refrained from disclosing specific reasoning behind the continued sales activity, and no new purchases were documented on April 13.
The stock settled at $4.12 during the April 13, 2026 close, supported by three Buy ratings and a $9.08 average price target from analysts.
